BioSpace News Archive

Business

Bluebird Faces Another Delay with BLA for Sickle Cell Gene Therapy

In an earnings call Wednesday, bluebird bio revealed it is unlikely to meet its first-quarter goal to submit a Biologics License Application for sickle cell disease (SCD) gene therapy lovo-cel.

March 30, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Biogen Successfully Targets Tau in Phase Ib Alzheimer’s Study

BIIB080 successfully reduced tau pathology in patients with early-stage disease across all six brain regions analyzed.

March 30, 2023
·
3 min read
·
Kate Goodwin
Policy

Court Sides with Vanda Against FDA in Freedom of Information Act Case

A federal court sided in favor of Vanda Pharmaceuticals in its Freedom of Information Act case against the FDA regarding the CRL for its sleep drug label expansion.

March 30, 2023
·
3 min read
·
Kate Goodwin
Drug Development

J&J Drops Out of RSV Race, Cuts Late-Stage Vaccine Candidate

The RSV race has lost one high-profile contender as Janssen announced it is discontinuing the Phase III EVERGREEN trial studying its RSV vaccine candidate.

March 30, 2023
·
2 min read
·
Tristan Manalac
Drug Development

GSK Expands Infectious Disease Pipeline With $593M SCYNEXIS Deal

GSK will help commercialize Brexafemme (ibrexafungerp), currently approved to treat vaginal yeast infections and vulvovaginal candidiasis (VVC).

March 30, 2023
·
2 min read
·
Ana Mulero
Employer Resources

Proximity Bias: Are In-Office Workers at an Advantage Over Remote Workers?

Proximity bias, a term that describes how managers tend to favor those they see in person, may force remote and hybrid workers to work harder to keep up with their in-person counterparts.

March 30, 2023
·
3 min read
·
Rosemary Scott
Policy

FDA approves Bioretec’s RemeOs™ trauma screw as the first bioresorbable metal implant in the U.S. market

Bioretec Ltd. has received market authorization for its RemeOs™ trauma screw in the U.S. The RemeOs™ trauma screw is the first and currently only bioresorbable metal implant approved by the U.S. Food and Drug Administration.

March 30, 2023
·
4 min read
Sensorion Announces the Publication of Its 2022 Annual Financial Report

Sensorion a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces that its Annual Financial Report for the year ending December 31, 2022, is available to the public and filed with the French financial market authority.

March 30, 2023
·
3 min read
Biotech Beach

Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced the pricing of its underwritten public offering of 17,242,000 shares of its common stock at a price to the public of $14.50 per share.

March 30, 2023
·
5 min read
Business

Hansa Biopharma publishes Annual Report 2022

Hansa Biopharma AB “Hansa”, a pioneer in enzyme technology for rare immunological conditions, announced the release of the Annual Report 2022.

March 30, 2023
·
5 min read